Trial Profile
Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Colecalciferol (Primary) ; Etanercept (Primary) ; GAD65 vaccine (Diamyd) (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms EDCR IIa
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Results presented in a Diamyd Medical AB Media Release,
- 27 Mar 2019 According to the Diamyd Medical AB media release, 30 months results from this study are expected to be presented in the spring of 2019